Transferable exclusivity extensions to stimulate antibiotic research and development: what is at stake?

Michael Anderson, Olivier J Wouters, Elias Mossialos

Division of Population Health, Health Services Research & Primary Care (L5)

Research output: Contribution to journal › Commentary/debate › peer-review

Original language	English
Pages (from-to)	e127-e128
Journal	The Lancet Microbe
Volume	4
Issue number	3
Early online date	2 Dec 2022
DOIs	https://doi.org/10.1016/S2666-5247(22)00336-6
Publication status	Published - 1 Mar 2023

Access to Document

10.1016/S2666-5247(22)00336-6Licence: CC BY-NC-ND

Other files and links

Link to publication in Scopus

Cite this

@article{d54e471e99f547ec93372678b42f8ac7,

title = "Transferable exclusivity extensions to stimulate antibiotic research and development: what is at stake?",

author = "Michael Anderson and Wouters, {Olivier J} and Elias Mossialos",

year = "2023",

month = mar,

day = "1",

doi = "10.1016/S2666-5247(22)00336-6",

language = "English",

volume = "4",

pages = "e127--e128",

journal = "The Lancet Microbe",

publisher = "The Lancet",

number = "3",

}

TY - JOUR

T1 - Transferable exclusivity extensions to stimulate antibiotic research and development: what is at stake?

AU - Anderson, Michael

AU - Wouters, Olivier J

AU - Mossialos, Elias

PY - 2023/3/1

Y1 - 2023/3/1

UR - http://www.scopus.com/inward/record.url?scp=85149062270&partnerID=8YFLogxK

U2 - 10.1016/S2666-5247(22)00336-6

DO - 10.1016/S2666-5247(22)00336-6

M3 - Commentary/debate

VL - 4

SP - e127-e128

JO - The Lancet Microbe

JF - The Lancet Microbe

IS - 3

ER -